Neetal Nevrekar, MD

CRS:

BJMC

Role:

Clinical

Position:

Research Clinician

Email:

drneetal24@gmail.com

Dr. Neetal Nevrekar is a research clinician at BJMC-CRS in Pune, India, where she has worked since June 2010. She is experienced in the field of clinical research on HIV, and works on various IMPAACT and ACTG Network research protocols. She worked on research protocols A5207, A5253, and A5225 as a research officer. Presently working on protocols 1077BF and 1077FF (PROMISE), A5282, A5288, and P1078 as a study clinician. 

She screens and enrolls research participants, is involved in developing the source documents for research protocols, and in completing clinical record forms. She is also responsible for adverse event reporting to RSC/DAIDS and for communications with Clinical Managing Committee (CMC) of the respective protocols eith regard to clinical management issues, toxicities, change of study drugs.

Dr. Nevrekar conducts training programs at the site for research staff, counselors and clinical personnel. She has received training in Good Clinical Practices and also completed web based GCP, HSP training. She was a member of Women’s Health Inter-network Scientific Committee (WHISC) for the IMPAACT and ACTG Network.

Dr. Nevrekar received an undergraduate degree from Grant Medical Institute, Mumbai, and a Doctor of Medicine in Obstetrics and Gynaecology from Grant Medical Institute and Bombay Hospital Research Centre. She worked as a senior medical officer at Bombay Hospital Research Centre for four years. Subsequently she was a consultant in Obstetrics and Gynaecology for six years.

  • “Vaginal delivery in a case of Pregnancy with Cervical Fibroid” - Journal of F.I.G.O, vol.49 no.2, page 77 dated April 1999.
  • “A Quadruplet Pregnancy” - Journal of F.I.G.O, vol.57 no.5, page 439-441 dated Sept-Oct. 2007.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More